| Darunavir Approved for Use with Boosted Ritonavir as Preferred PI, Pediatric Dosing |  | | HIV Meds Quarterly Research Brief | | Winter 2009 | | Susa Coffey, MD, HIV InSite Medical Editor | | Ian R. McNicholl, PharmD, BCPS (Added Qualifications-Infectious Diseases), HIV InSite Pharmacy Editor |  | |
DHHS recommendations: The DHHS adult and adolescent ARV guidelines now include ritonavir-boosted darunavir, given once daily, as a "Preferred" protease inhibitor for initial treatment. This recommendation is based on results of a randomized open-label noninferiority study comparing once-daily darunavir/ritonavir with lopinavir/ritonavir (given once or twice daily), in treatment-naive patients. All patients also received tenofovir + emtricitabine. At 48 weeks, HIV RNA levels were suppressed to <50 copies/mL in 84% of darunavir recipients and 76% of lopinavir recipients. For those with baseline HIV RNA levels >100,000 copies/mL, the rate of virologic suppression was significantly higher in the darunavir arm than in the lopinavir arms (79% vs 67%; p < .05). The recommended dosage for initial therapy is darunavir 800 mg BID + ritonavir 100 mg BID. Pediatric approval: The FDA recently approved pediatric dosing recommendations for darunavir for children aged 6 years and older, and a new 75 mg tablet formulation. Recommended dosage is shown in the table below. Once-daily dosing of darunavir should not be used in pediatric patients. | Age/Weight | Pediatric Darunavir Dosage |
|---|
| Age <6 years or weight <20 kg | Not FDA approved | | Age 6 to <18 years | | Wt ≥20 kg to <30 kg | Darunavir 375 mg BID + ritonavir 50 mg BID | | Wt ≥30 kg to <40 kg | Darunavir 450 mg BID + ritonavir 60 mg BID | | Wt ≥40 kg | Darunavir 600 mg BID + ritonavir 100 mg BID (adult dosage) |
|
| |
|
|
HIV InSite is a project of the UCSF Center for HIV Information. Copyright 2013, Regents of the University of California.